Clinical Trial Update: Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating whether proteomic profiling can predict response to erlotinib in patients with stage IIIB/IV or recurrent non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-04-25